{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:03:06Z","timestamp":1782907386700,"version":"3.54.5"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Kidneys from donors with hepatitis C virus (HCV) infection are traditionally considered to be at risk for poorer survival outcomes, as reflected in the kidney donor profile index (KDPI). Modern direct-acting antivirals may modify this risk.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>Using United Network for Organ Sharing data, HCV-infected adult first-time kidney transplant recipients from 2014 to 2017 were examined. Graft and patient survival were compared in a propensity-matched cohort of recipients of HCV antibody (Ab)(+) kidneys versus Ab(-) kidneys. Subsequent analysis was performed in a propensity-matched cohort of recipients of HCV-viremic (RNA positive) versus HCV-na\u00efve kidneys.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>There were 379 recipients each in the matched cohort of recipients of HCV Ab(+) versus HCV Ab(-) kidneys. Despite a higher KDPI (58.2% for HCV Ab[+] versus 38.8% for HCV Ab[-]), 1-year patient and graft survival were similar in the HCV(+) and HCV(-) groups (95.4% and 94.9% versus 97.9% and 96.0%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.543 and <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.834, respectively). There were 200 recipients each in the cohort of recipients of HCV-viremic versus HCV-na\u00efve kidneys, with the KDPI again higher in the HCV-viremic group (56.8% versus 35.2%). Baseline hazard ratios (HRs) for graft failure (HR, 4.69; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.009) and death (HR, 7.60; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.003) were significantly elevated in the viremic group, but crossed 1 at 21 and 24 months, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>In the modern direct-acting antiviral era, calculated likely KDPI overestimates risk kidneys from HCV (+) donors. Donor viremia conveys an early risk which appears to subside over time. These results suggest that it may be time to revise the kidney donor risk index.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000002949","type":"journal-article","created":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T02:08:45Z","timestamp":1568340525000},"page":"1215-1228","source":"Crossref","is-referenced-by-count":26,"title":["Impact of Donor Hepatitis C Virus on Kidney Transplant Outcomes for Hepatitis C-positive Recipients in the Direct-acting Antiviral Era: Time to Revise the Kidney Donor Risk Index?"],"prefix":"10.1097","volume":"104","author":[{"given":"Robert M.","family":"Cannon","sequence":"first","affiliation":[{"name":"Department of Surgery, Division of Transplantation, University of Alabama at Birmingham, Birmingham, AL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayme E.","family":"Locke","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Transplantation, University of Alabama at Birmingham, Birmingham, AL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak J.","family":"Orandi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Transplantation, University of Alabama at Birmingham, Birmingham, AL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas J.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Transplantation, University of Alabama at Birmingham, Birmingham, AL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric G.","family":"Davis","sequence":"additional","affiliation":[{"name":"Hiram C. Polk Jr. MD Department of Surgery, Division of Transplantation, University of Louisville, Louisville, KY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Mackelaite","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology and Hypertension, University of Louisville, Louisville, KY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitarth","family":"Dave","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology and Hypertension, University of Louisville, Louisville, KY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Eng","sequence":"additional","affiliation":[{"name":"Hiram C. Polk Jr. MD Department of Surgery, Division of Transplantation, University of Louisville, Louisville, KY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Jones","sequence":"additional","affiliation":[{"name":"Hiram C. Polk Jr. MD Department of Surgery, Division of Transplantation, University of Louisville, Louisville, KY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"11","key":"R1-20231002","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1097\/01.ASN.0000090743.43034.72","article-title":"Hepatitis C and renal transplantation in the era of modern immunosuppression.","volume":"14","author":"Abbott","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"R2-20231002","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1097\/01.ASN.0000034944.90425.75","article-title":"Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation.","volume":"13","author":"Bucci","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R3-20231002","first-page":"51","article-title":"Outcomes associated with recipient and donor hepatitis C serology status after kidney transplantation in the United States: analysis of the USRDS\/UNOS database.","author":"Bucci","year":"2004","journal-title":"Clin Transpl"},{"issue":"5","key":"R4-20231002","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1600-6143.2010.03091.x","article-title":"Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients.","volume":"10","author":"Kucirka","year":"2010","journal-title":"Am J Transplant"},{"issue":"4","key":"R5-20231002","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/ckj\/sfx048","article-title":"Effect of kidney donor hepatitis C virus serostatus on renal transplant recipient and allograft outcomes.","volume":"10","author":"Cohen","year":"2017","journal-title":"Clin Kidney J"},{"issue":"2","key":"R6-20231002","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/TP.0b013e3181ac620b","article-title":"A comprehensive risk quantification score for deceased donor kidneys: the kidney donor risk index.","volume":"88","author":"Rao","year":"2009","journal-title":"Transplantation"},{"issue":"10","key":"R7-20231002","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1111\/ajt.14701","article-title":"Are we underestimating the quality of aviremic hepatitis C-positive kidneys? Time to reconsider.","volume":"18","author":"Sibulesky","year":"2018","journal-title":"Am J Transplant"},{"issue":"10","key":"R9-20231002","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1111\/ajt.14895","article-title":"The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes.","volume":"18","author":"Axelrod","year":"2018","journal-title":"Am J Transplant"},{"issue":"1","key":"R10-20231002","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/hep.27890","article-title":"Safety and tolerability of ledipasvir\/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials.","volume":"62","author":"Alqahtani","year":"2015","journal-title":"Hepatology"},{"issue":"3","key":"R11-20231002","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease.","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"issue":"2","key":"R12-20231002","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.","volume":"67","author":"Kwo","year":"2017","journal-title":"J Hepatol"},{"issue":"5","key":"R13-20231002","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40265-018-0895-5","article-title":"Sofosbuvir\/velpatasvir\/voxilaprevir: a review in chronic hepatitis C.","volume":"78","author":"Heo","year":"2018","journal-title":"Drugs"},{"issue":"27","key":"R14-20231002","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis.","volume":"373","author":"Curry","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"R16-20231002","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects.","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"issue":"3","key":"R17-20231002","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies.","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"4","key":"R18-20231002","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0895-4356(00)00321-8","article-title":"Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores.","volume":"54","author":"Normand","year":"2001","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"R19-20231002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/096228029900800102","article-title":"Multiple imputation: a primer.","volume":"8","author":"Schafer","year":"1999","journal-title":"Stat Methods Med Res"},{"issue":"7","key":"R20-20231002","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1111\/ajt.13717","article-title":"Survival analysis in the presence of competing risks: the example of waitlisted kidney transplant candidates.","volume":"16","author":"Sapir-Pichhadze","year":"2016","journal-title":"Am J Transplant"},{"issue":"7","key":"R22-20231002","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1016\/j.transproceed.2010.04.056","article-title":"Kidney grafts from HCV-positive donors: advantages and disadvantages.","volume":"42","author":"Maluf","year":"2010","journal-title":"Transplant Proc"},{"issue":"7","key":"R23-20231002","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJM199302183280703","article-title":"Membranoproliferative glomerulonephritis associated with hepatitis C virus infection.","volume":"328","author":"Johnson","year":"1993","journal-title":"N Engl J Med"},{"issue":"2","key":"R24-20231002","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1034\/j.1600-6143.2001.10212.x","article-title":"Hepatitis C virus infection and de novo glomerular lesions in renal allografts.","volume":"1","author":"Cruzado","year":"2001","journal-title":"Am J Transplant"},{"issue":"4","key":"R26-20231002","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/hep.30046","article-title":"Glecaprevir\/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection.","volume":"68","author":"Reau","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"R27-20231002","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/M18-0749","article-title":"Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: a single-group trial.","volume":"169","author":"Reese","year":"2018","journal-title":"Ann Intern Med"},{"issue":"10","key":"R29-20231002","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1111\/ajt.13971","article-title":"Improving organ utilization to help overcome the tragedies of the opioid epidemic.","volume":"16","author":"Goldberg","year":"2016","journal-title":"Am J Transplant"},{"issue":"12","key":"R30-20231002","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1097\/TP.0000000000002323","article-title":"Changes in utilization and discard of HCV antibody-positive deceased donor kidneys in the era of direct-acting antiviral therapy.","volume":"102","author":"Bowring","year":"2018","journal-title":"Transplantation"},{"issue":"11","key":"R31-20231002","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1111\/ajt.14381","article-title":"The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation.","volume":"17","author":"Levitsky","year":"2017","journal-title":"Am J Transplant"},{"issue":"2","key":"R32-20231002","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/ajt.13976","article-title":"Changes in utilization and discard of hepatitis C-infected donor livers in the recent era.","volume":"17","author":"Bowring","year":"2017","journal-title":"Am J Transplant"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000002949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:00:39Z","timestamp":1696222839000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000002949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000002949","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}